Farmaceuticos Comunitarios最新文献

{"title":"[Inhaled Respiratory Therapy and Global Warming].","authors":"C Casanova-Martínez, E Espino-Paisán, L Buján-de-Gonzalo, M Lema-Oreiro, M J Álvarez-Sánchez","doi":"10.33620/FC.2173-9218.(2025).11","DOIUrl":"10.33620/FC.2173-9218.(2025).11","url":null,"abstract":"<p><strong>Introduction: </strong>Hydrofluorocarbon (HFC) propellants used in current pressurized metered-dose inhalers (pMDIs) act as potent greenhouse gases, contributing to global warming. The objective of this study is to analyse the type and pattern of use of inhaler use in the Galician population, as well as to assess its impact on the carbon footprint.</p><p><strong>Methodology: </strong>This is an observational, descriptive, and retrospective study conducted in the autonomous community of Galicia in 2023. It included patients receiving pharmaceutical care from the Galician Health Service (SERGAS) who are being treated with bronchial inhalers for the management of their respiratory conditions.</p><p><strong>Results: </strong>A total of 1.711.344 inhaler units were dispensed, equivalent to a carbon footprint of 15.247.142 kg CO2eq. pMDIs accounted for 43,17% (738.707) of the units dispensed in 2023, corresponding to almost 95,43% of the carbon footprint emitted by inhalers, with HFA-134a being the most used propellant (669.907 units).</p><p><strong>Conclusions: </strong>pMDIs contribute to global warming, generating nearly the entire carbon footprint emitted by inhalers used in respiratory therapy. SERGAS has implemented several strategies to reduce the environmental impact caused by pMDIs.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 2","pages":"21-29"},"PeriodicalIF":0.5,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Adherence Improvement in Transplant Patient after Being Included in Medication Reconditioning Service].","authors":"M E Sánchez-Calero, D Pérez-Sánchez","doi":"10.33620/FC.2173-9218.(2025).10","DOIUrl":"10.33620/FC.2173-9218.(2025).10","url":null,"abstract":"<p><p>Male patient, 75 years of age, pluripathological and polymedicated. He underwent a liver transplant in 2006 so he was followed up by two hospitals in different provinces (Madrid and Castilla-La Mancha) which made the review even more difficult. the last few months, the pharmacists have noticed various discrepancies when dispensing his electronic prescriptions. We decided to offer him the Monitored Dosage Systems (MDS). He is a vulnerable patient given his pathologies and meets all the requirements to include him in the program.In a first interview, the patient is confused with the medication, he brings us full boxes of some medications and others are missing, suspecting that he does not follow the dosage indicated by the doctor, with the consequent lack of adherence to treatment.After the medication review, we found different Drug-Related Problems (DRPs): duplicity and dosage, regimen and/or inadequate duration. We contacted the primary care physician (GP) and the gastroenterologist to review the prescribed medication.After 8 months of being included in the MDS service, there has been a positive impact on the patient. He's health has significantly improved; he has gained weight, decreased the number of medication and improved his therapeutic adherence.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 2","pages":"15-20"},"PeriodicalIF":0.5,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The International Collaboration of Pharmacy Journal Editors (ICPJE) formally constituted to foster quality around clinical and social pharmacy practice research publications].","authors":"F Alves Da Costa, F Fernandez-Llimos, S Desselle, I Arnet, Z Babar, Ch Bond, M Cordina, V Garcia Cardenas, M El Hajj, R Jacobsen, A W Law, L S Nørgaard, C Polidori, N Shcherbakova, D Stewart, F S Tonin, A E Weidmann","doi":"10.33620/FC.2173-9218.(2025).08","DOIUrl":"10.33620/FC.2173-9218.(2025).08","url":null,"abstract":"<p><strong>Resumen: </strong>The Granada statements were a result of the need to strengthen clinical, social and administrative pharmacy practice as an area of knowledge that translates into practice, research and policy. As a re-sponse, a group of clinical and social pharmacy practice journal editors launched an initiative in Grana-da in 2022 to discuss ways to improve the quality of publications in this area, which culminated in the Granada statements. Eighteen statements were developed, clustered into six main domains:1) the ap-propriate use of terminology; 2) developing impactful abstracts; 3) having the required peer reviews; 4) preventing journal scattering; 5) more effective and wiser use of journal and article performance met-rics; and 6) authors' selection of the most appropriate pharmacy practice journal to submit their work.The full Granada statements have been published in 14 journals.(1-14) These pioneering statements are rooted in similar endeavors undertaken by scholars in other health professions groups, fostering the concept of interdisciplinary consensus and advancing scientific paradigm.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 2","pages":"5-10"},"PeriodicalIF":0.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[SEFAC 2025 Conference: Community pharmacy facing the challenge of specialisation and change].","authors":"Leire Andraca, José Luis Allué","doi":"10.33620/FC.2173-9218.(2025).01","DOIUrl":"10.33620/FC.2173-9218.(2025).01","url":null,"abstract":"<p><p>In 2025, which marks the 25th anniversary of our scientific society, SEFAC will be celebrating its national conference under the slogan 'Community pharmacy as a health, scientific and specialised profession', which attempts to encapsulate the essence of this period of transformation for the profession. Embracing change is not just an option but a necessity to ensure a solid and recognised future. As part of the 15th Conference, the professional debate 'Speciality in community pharmacy: a necessity?' will be held, which will serve to reflect on the path towards the consolidation of a specialisation that legitimises and further enhances the role of the community pharmacist within the healthcare system.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 1","pages":"3-4"},"PeriodicalIF":0.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of Ambulatory Blood Pressure Monitoring on patient health in remote areas: the role of Community Pharmacy].","authors":"Cristina Díaz-Jiménez","doi":"10.33620/FC.2173-9218.(2025).07","DOIUrl":"10.33620/FC.2173-9218.(2025).07","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular disease remains the leading cause of death. Arterial hypertension is the main avoidable risk factor. Scientific societies advise control methods such as Ambulatory Blood Pressure Monitoring (ABPM) but this technique is not usually available in rural settings.The aim of this study was to evaluate the effectiveness of pharmaceutical intervention using ABPM in community pharmacies.</p><p><strong>Material and method: </strong>Observational study conducted in a rural community pharmacy between July 2021 and December 2023. Patients over 18 years of age who were normotensive or had a previous diagnosis of hypertension were selected. They were fitted with a MicrolifeWatch BP03 device for 29 hours. Patients with results compatible with HT were referred to their primary care physician.</p><p><strong>Results: </strong>Twenty-one patients were included, of whom 20 were referred to the physician and treatment adjustments were made. Patient satisfaction was high, highlighting the accessibility of the service in the community pharmacy.</p><p><strong>Conclusion: </strong>The accessibility and proximity of community pharmacies, especially in rural areas, facilitates the application of MAPA, improving the control of HTN.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 1","pages":"40-44"},"PeriodicalIF":0.5,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Strong Professional identity construction as a change lever].","authors":"Miguel Angel Gastelurrutia","doi":"10.33620/FC.2173-9218.(2025).06","DOIUrl":"10.33620/FC.2173-9218.(2025).06","url":null,"abstract":"<p><p>Professional identity is the way in which professionals define themselves in relation to their professional role, encompassing both their sense of identity and the expected behaviors associated with that role. The formation of this identity is a complex process that begins at the undergraduate level and continues throughout a pharmacist's professional career. Several different professional identities have been identified in the world of pharmacy, which may indicate a degree of ambiguity in the role expected of this professional and a lack of clear direction and characterization of what makes the pharmacist \"unique\", although it may also suggest a flexible and broad view of the pharmacist's role. For the clinical role promoted by the various professional organizations at the international level to become a reality, and for the profession to be re-professionalized, students need to build a solid identity, and this work must begin at the undergraduate level. With the publication of the recent Delegated Directive (EU) 2024/782, a window of opportunity has opened for both the university and the profession to discuss where the profession should go and, more specifically, what the professional role of the pharmacist should be.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 1","pages":"34-39"},"PeriodicalIF":0.5,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Role of Community Pharmacies in the Secondary Prevention of Skin Cancer].","authors":"Augusto González Borrego, María Reyes Jiménez Blanco","doi":"10.33620/FC.2173-9218.(2025).05","DOIUrl":"10.33620/FC.2173-9218.(2025).05","url":null,"abstract":"<p><strong>Introduction: </strong>Skin cancer prevention is a public health priority due to its high incidence and potential to cause significant morbidity and mortality. This study evaluated the effectiveness of an early skin cancer detection program in a community pharmacy, utilizing advanced technologies and interdisciplinary collaboration.</p><p><strong>Objectives: </strong>1. Early detection of melanoma and non-melanoma skin cancer in patients visiting the community pharmacy. 2. Facilitate patient referral to a dermatologist through the pharmacy.</p><p><strong>Material and methods: </strong>A cross-sectional observational study was conducted in a community pharmacy between June 2018 and September 2023. Adult patients concerned about skin lesions were included. After obtaining written informed consent, an interview was conducted, and photographs of the lesions were taken and electronically sent to a dermatology service for a preliminary diagnosis within 24-48 hours.</p><p><strong>Results: </strong>A total of 41 patients were evaluated (51% men; 54% over 50 years old). Benign lesions were identified in 54% of cases, avoiding unnecessary consultations and optimizing health resources. 46% presented suspicious cancer lesions requiring detailed evaluation, with 63% of this group being over 60 years old. More than 85% of the preliminary diagnoses were accurate with the images sent.</p><p><strong>Discussion: </strong>The results underscore the effectiveness of early detection programs in community pharmacies for identifying benign and suspicious lesions, optimizing resources, and facilitating early interventions. The collaboration between pharmacists and dermatologists, along with the use of advanced technologies, were key to the program's success. However, the study's limitations include the sample size and its focus on a single pharmacy.</p><p><strong>Conclusions: </strong>Community pharmacies can play a crucial role in the secondary prevention of skin cancer, improving healthcare system efficiency and benefiting patients through early detection and timely intervention. Future studies with larger samples are recommended to validate these findings and quantify resource optimization.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 1","pages":"28-33"},"PeriodicalIF":0.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[MUR and MCA: allies to guarantee therapeutic success].","authors":"Cristina Díaz López","doi":"10.33620/FC.2173-9218.(2025).04","DOIUrl":"10.33620/FC.2173-9218.(2025).04","url":null,"abstract":"<p><p>A 73-year-old, dependent, polymedicated, multi-pathological patient contacts the Community Pharmacy by telephone to request information on a newly prescribed treatment for a urinary tract infection and vitamin D deficiency. The dispensing of the medication to her caregiver leads to further doubts for the patient, so she is offered the Medication Use Review (MUR) service. During the service, several incidences are detected in her treatment, so it is decided to make a referral report to the Primary Care Physician for a complete review of the treatment and thus be able to refer the patient to the Personalized Dosage System (SPD) service in order to guarantee the patient's pharmacotherapeutic safety and improve her adherence to the treatment. In this case, the provision of the RUM service served as a gateway to the SPD and made it possible to detect Medication Related Problems (MRP) that could lead to therapeutic failure.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 1","pages":"21-27"},"PeriodicalIF":0.5,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Review of patients' medicine aid kits by community pharmacies in Alava].","authors":"Carmen Vinagre Sánchez, Maite Ibarra Barrueta, Margarita Mosteiro, Mercedes Villacorta, Miriam Sáenz de Santamaría","doi":"10.33620/FC.2173-9218.(2025).03","DOIUrl":"10.33620/FC.2173-9218.(2025).03","url":null,"abstract":"<p><strong>Introduction: </strong>The medicines aid kits revision services is a Clinical Professional Pharmacy Service that aims to increase patients' knowledge about their medication, (What it is for, how to take it, how to preserve…). It also promotes proper management of expired and/or unused medicines, (disposal at punto SIGRE in pharmacies) to reduce their environmental impact.</p><p><strong>Objective: </strong>To review the medicines, medical devices, and/or self-care products that the patient has at home, to record any incidents detected, and any pharmaceutical interventions carried out.</p><p><strong>Material and methods: </strong>The campaign was open to all pharmacies in Alava. Participating pharmacies, after completing specific training, reviewed medicines aid kits and filled in an electronic form with the collected data. Finally, the data were analysed.</p><p><strong>Results: </strong>The main pharmaceutical interventions were to dispose of expired medicines at point SIGRE, inform about appropriate use and storage at home.</p><p><strong>Discussion: </strong>This study reinforces the role of the pharmacist within the health system as an indispensable agent in improving patient health.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 1","pages":"11-20"},"PeriodicalIF":0.5,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Anticholinergic burden in the elderly].","authors":"M Rodríguez Casal","doi":"10.33620/FC.2173-9218.(2025).02","DOIUrl":"10.33620/FC.2173-9218.(2025).02","url":null,"abstract":"<p><p>Anticholinergic drugs are widely used for very common diseases such as Parkinson's disease, depression or allergies, but it has been observed in previous studies that high anticholinergic burden can lead to physical and cognitive dysfunctions in polymedicated elderly people. The objective of this project is to review these hypotheses and study the possible relationship between high anticholinergic burden and cognitive and physical dysfunctions.In terms of methodology, a bibliographic review has been carried out of the information that exists to date on the hypothesis that high anticholinergic burden can lead to both physical and cognitive dysfunctions in elderly people taking multiple medications, and a cross-sectional study has been designed that included patients over 70 years and taking multiple medications to calculate the anticholinergic burden of their medication and determine whether high levels of it could have any influence on the deterioration of the patients.At the end of the study, it was observed high prevalence of prescriptions of medications with high anticholinergic burden in elderly patients, with its consequences in terms of adverse effects. These results lead us to the conclusion of the need to take into account the anticholinergic burden of medications when prescribing.</p>","PeriodicalId":40648,"journal":{"name":"Farmaceuticos Comunitarios","volume":"17 1","pages":"5-10"},"PeriodicalIF":0.5,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}